R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin-Reference-Cited by-同舟云学术

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

Published:2008-08 Issue:2 Volume:48 Page:385-397
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Pockros Paul J.,Nelson David,Godofsky Eliot,Rodriguez-Torres Maribel,Everson Gregory T.,Fried Michael W.,Ghalib Reem,Harrison Stephen,Nyberg Lisa,Shiffman Mitchell L.,Najera Isabel,Chan Anna,Hill George

Publisher

Wiley

Subject

Hepatology

Reference22 articles.

1. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients;Torriani;N Engl J Med,2004

4. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons;Chung;N Engl J Med,2004

5. Treating hepatitis C in “difficult-to-treat” patients;Pawlotsky;N Engl J Med,2004

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunochromatographic Technique for Seropositivity and PCR Based Molecular Diagnosis for Hepatis B and C Virus in a General Population of Mansehra Pakistan;Abasyn Journal Life Sciences;2020-06-29

2. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold;Antiviral Research;2019-02

3. Direct-acting antivirals for chronic hepatitis C;Cochrane Database of Systematic Reviews;2017-09-18

4. Direct-acting antivirals for chronic hepatitis C;Cochrane Database of Systematic Reviews;2017-06-06

5. Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection;Comprehensive Medicinal Chemistry III;2017